Suppression of the inflammatory response by disease-inducible interleukin-10 gene therapy in a three-dimensional micromass model of the human synovial membrane
© The Author(s). 2016
Received: 30 March 2016
Accepted: 26 July 2016
Published: 12 August 2016
Gene therapy has the potential to provide long-term production of therapeutic proteins in the joints of osteoarthritis (OA) patients. The objective of this study was to analyse the therapeutic potential of disease-inducible expression of anti-inflammatory interleukin-10 (IL-10) in the three-dimensional micromass model of the human synovial membrane.
Synovial tissue samples from OA patients were digested and the cells were mixed with Matrigel to obtain 3D micromasses. The CXCL10 promoter combined with the firefly luciferase reporter in a lentiviral vector was used to determine the response of the CXCL10 promoter to tumour necrosis factor alpha (TNF-α), interleukin-1β (IL-1β) and lipopolysaccharide (LPS). The effects of recombinant IL-10 on gene expression were determined by quantitative PCR. The production of IL-10 from the CXCL10p-IL10 vector and the effects on pro-inflammatory cytokine production were assessed by multiplex ELISA.
Micromasses made from whole synovial membrane cell suspensions form a distinct surface composition containing macrophage and fibroblast-like synoviocytes thus mimicking the synovial lining. This lining can be transduced by lentiviruses and allow CXCL-10 promoter-regulated transgene expression. Adequate amounts of IL-10 transgene were produced after stimulation with pro-inflammatory factors able to reduce the production of synovial IL-1β and IL-6.
Synovial micromasses are a suitable model to test disease-regulated gene therapy approaches and the CXCL10p-IL10 vector might be a good candidate to decrease the inflammatory response implicated in the pathogenesis of OA.
KeywordsOsteoarthritis Gene therapy Cytokines Micromasses Synovium Inflammation
Osteoarthritis (OA) is the most common joint disease and no adequate disease-modifying treatments are available yet . Although the exact etiology of OA is still unclear and may be dependent on multiple risk factors, there is increasing evidence that in many OA patients inflammation is involved in the pathogenesis . Interleukin-1β (IL-1β) and tumour necrosis factor alpha (TNF-α) are key pro-inflammatory cytokines, primarily produced by macrophages that infiltrate the synovium during inflammatory OA . These cytokines trigger the release of other cytokines and matrix-degrading enzymes from resident articular cells, including the fibroblast-like synoviocytes (FLS) that damage the articular cartilage. This results in the release of damage-associated molecular patterns (DAMPs) with pro-inflammatory properties, potentially creating a positive vicious circle of inflammation and damage .
Several strategies have been explored to treat inflammation in the OA joint, including biological therapies that were developed for the treatment of rheumatoid arthritis (RA). However, the therapeutic effects are disappointing . A possible explanation might be the relatively strong contribution of systemic factors in RA. In contrast, OA is considered primarily to be a local process and systemically injected therapeutics may not reach the target joints in sufficient amounts. Intra-articular injections are feasible but proteins injected in the joint are rapidly cleared and consequently the invasive injections have to be repeated increasing the discomfort for patients . These considerations ask for the development of a different strategy to obtain long-term drug effects in the OA joint. Local gene therapy can be a suitable approach and might even be used to express proteins with a short half-life like interleukin-10 (IL-10), which is a potent anti-inflammatory cytokine .
Previous studies with IL-10 gene therapy in experimental models of rheumatoid arthritis have explored the use of inducible promoters to drive the expression of IL-10 [8–10]. These promoters contain binding sites for transcription factors that are activated during active disease, which might reduce side effects of continuous IL-10 exposure as observed in patients suffering from chronic active Crohn’s disease. These patients received daily injections of high-dose IL-10 and showed a drop in haemoglobin levels . We recently adapted the inducible IL-10 gene therapy to human synovial cells . For this purpose, the promoter from the CXCL10 gene was selected based on microarray analysis of RA synovium. The inflammatory C-X-C motif chemokine 10 (CXCL10) protein concentration has also been found to be significantly upregulated in the synovial fluid and in the serum of OA patients compared to healthy controls [13, 14]. Because CXCL10 can be expressed from multiple cell types, no selective expression is expected from the vector . CXCL10 expression is associated with OA-related disease processes, including inflammation and osteoclastogenesis , which indicates that CXCL10 promoter-driven expression of IL-10 might be a viable option for the treatment of OA. In addition, the OA synovium could be more sensitive to IL-10 therapy, because of relatively high expression of the IL-10 receptor alpha chain as compared to RA .
The CXCL10p-IL10 gene therapy approach showed promising results in synovial cell suspensions. Based on the known IL-10 effects we postulate that local IL-10 gene therapy would be efficacious at the early stage of OA when synovitis is developing and before irreversible fibrotic changes occur. In this study, we determined the inflammatory response and anti-inflammatory potential of the CXCL10p-IL10 lentiviral vector in the three-dimensional (3D) micromass synovial membrane model. In a 3D culture model, the cell-matrix and cell-cell interactions are more biologically relevant, providing a more predictive system for the in vivo situation, compared to classic two-dimensional (2D) culture . Synovial micromasses were generated from primary synovial cells isolated from OA patients by digestion, containing both FLS and macrophage-like synoviocytes (MLS). The micromasses were transduced after establishment of a synovial lining layer and the CXCL10 promoter was responsive to lipopolysaccharide (LPS), TNF-α and IL-1β. The activated promoter could provide therapeutic quantities of IL-10, which reduced the release of IL-1β and IL-6. These results show that the CXCL10p-IL10 vector can provide self-regulated inhibition of the inflammatory response in a synovial membrane model.
The synovial samples were digested using 50 μg/ml Liberase TM (Roche, Basel, Switzerland) for 1 h at 37 °C in Roswell Park Memorial Institute (RPMI) culture medium without supplementations. The digestion was stopped by adding 10 % fetal calf serum (FCS). Subsequently, the synovial cells were passed through a 70-μm cell strainer (Corning, NY, USA) and centrifuged. All cell centrifugations were performed for 5 min at 1500 rpm/423 g in a Heraeus Megafuge 16R (Thermo Fisher Scientific). Red blood cells were lysed for 2 min at RT using 4 ml RBC lysis buffer (155 nM NH4Cl, 12 mM KHCO3, 0.1 mM EDTA, pH 7.3). The lysis reaction was quenched by adding 6 ml RPMI culture medium, supplemented with 10 % FCS and 1 mM pyruvate and 1 % P/S.
Micromass production and culture
For micromass construction, the synovial cell suspensions were centrifuged and cell pellets were dissolved in ice-cold Matrigel (Corning) at an average density of 2 × 10E7 cells/ml. Using cooled pipette tips, 25 μl droplets were placed in 24-well culture plates (Greiner Bio-one, Alphen a/d Rijn, The Netherlands) or conical 12 ml tubes (Greiner Bio-one), which were coated with poly-(2-hydroxyethyl methacrylate) (poly-HEMA) (Sigma-Aldrich, Zwijndrecht, The Netherlands). After 30 minutes gelation at 37 °C, 500 μl RPMI culture medium, supplemented with 10 % heat-inactivated FCS, 1 mM pyruvate and 1 % P/S was added. Medium was replaced twice weekly. All cell cultures were kept in humidified atmosphere at 37 °C and 5 % CO2. The micromasses were stimulated with E. coli lipopolysaccharide (LPS) (Invivogen, San Diego, CA, USA), recombinant human TNF-α (Abcam, Cambridge, UK), recombinant human IL-1β (R&D systems, Oxford, UK) and recombinant human IL-10 (Life Technologies Europe, Bleiswijk, The Netherlands) at concentrations and timing as indicated in the text.
For immunohistochemical analysis, micromasses were fixated for 2 h in 2 % paraformaldehyde in phosphate-buffered saline (PBS)/1 mM CaCl2, dehydrated and embedded in paraffin. Sections 7-μm thick were deparaffinized, rehydrated and incubated with antibodies 11-fibrau (1:100 for 60 minutes) (clone D7-fib, Imgen, distributed by ITK Diagnostics, Uithoorn, The Netherlands), mouse anti-human cluster of differentiation 68 (CD68) (1:100 for 60 minutes) (M0814, DAKO, Heverlee, Belgium) or control mouse IgG2ak (X0943, DAKO) and IgG1k (X0931, DAKO) respectively. Endogenous peroxidase activity was blocked with 3 % H2O2 (Merck Millipore, Amsterdam, The Netherlands) in methanol. Subsequently, the sections were incubated with the secondary horseradish peroxidase (HRP)-conjugated rabbit-anti-mouse IgA/G/M (1:200 for 60 minutes) (P0260, DAKO). Peroxidase was developed with diaminobenzidine and counterstained with hematoxylin for 60 seconds.
Plasmid cloning and lentivirus production
List of oligonucleotide primer sequence
Sequence (5′ → 3′)
For confocal microscopy, day 9 micromasses produced from an OA patient were transduced with lentiviral PGK-GFP and fixed in 1 % paraformaldehyde, 48 h after transduction. Micromasses were stained with DAPI (Molecular Probes, Eugene, OR, USA) at a concentration of 0.2 ug/ml in PBS for 10 minutes, followed by three washing steps in PBS. Micromasses were mounted in Fluoromount-G (Southern Biotech, Birmingham, AL, USA). Confocal pictures were taken at ×200 magnification using the Olympus Fluoview FV1000 laser scanning microscope (Olympus, Zoeterwoude, The Netherlands). 4′,6-diamidino-2-phenylindole (DAPI) and green fluorescent protein (GFP) were imaged using lasers at excitation wavelengths of 405 nm and 488 nm respectively. Image processing was performed using the Fluoview Viewer Software V4.1 (Olympus).
For flow cytometry analysis, micromasses were melted on ice for 2 h, 48 h after transduction with lentiviral PGK-GFP. The cell suspension was incubated with antibodies 11-Fibrau and subsequently with donkey-anti-mouse conjugated to Alexa Fluor 568 (1:100 for 30 minutes) (A-10037, Thermo Fisher Scientific), or cell suspensions were incubated with mouse-anti-human CD68, conjugated to PE (1:20 for 60 minutes) (12-0689, eBioscience, San Diego, CA, USA). The flow cytometry was performed on the FACS Cyan (Beckman Coulter, Woerden, The Netherlands) using the 488 nm laser at the FL1, FL3 and FL7 channels for GFP, 11-Fibrau and CD68 respectively.
The luciferase measurements were performed in 96-well white clear-bottom plates (Greiner Bio-one) using the Dual-Glo luciferase assay system (Promega). Micromasses were transferred to a well and lysed in Dual-Glo reagent for 10 minutes. Firefly luciferase light production was measured on a Clariostar (BMG, Offenburg, Germany). Subsequently, the lysates were incubated for 10 minutes with Stop & Glo before measuring the Renilla luciferase light production. The values were corrected for the background signal and depicted as relative light units (RLU).
RNA isolation and quantitative polymerase chain reaction (qPCR)
Multiplex enzyme-linked immunosorbent assay (ELISA) assay
Cytokine concentrations were determined by luminex multianalyte technology on the Bio-Plex 200 (Bio-Rad, Hercules, CA, USA) in combination with Bio-Plex pro human cytokine kits (Bio-Rad) according to the manufacturer’s protocol. For IL-10 and interleukin-6 (IL-6) measurements, the micromass culture supernatants were first diluted 25 times. Samples below the detection limit were set at the lowest measureable quantity to perform statistical analysis.
Statistical analysis was performed using the Student’s t test, one-way analysis of variance (ANOVA) and two-way ANOVA. Results are depicted as mean +/- SD and P values < 0.05 were regarded as significant. For statistical comparisons between conditions including multiple patients, patients were first individually normalized for the control conditions.
The synovial micromass membrane contains FLS and MLS
In previous studies that used the synovial micromass model, primary FLS were used that had been cultured for multiple passages. However, sustained culture of FLS can result in phenotype alterations  and in FLS micromasses the contribution of MLS is omitted. Therefore, we first tested the ability of synovial cell suspensions derived from digested synovium to form a lining layer in micromass culture. After 7 days, cells had migrated to the micromass-medium interface and resembled a synovial membrane (Fig. 1). The sections were stained using the 11-fibrau antibody, which revealed that most cells in the lining are synovial fibroblast-like cells (Fig. 1b). In addition, we performed a staining for the macrophage marker CD68. Macrophages were also present in the micromasses and appeared in the lining at day 7 (Fig. 1d). This shows that the synovial micromass model can be used to study a membrane that resembles the architecture and composition of the synovial lining. When the micromasses were transduced with a lentiviral PGK-GFP vector, GFP expression was mainly observed in the lining layer (Fig. 1e) and to a lesser extent in the sublining. The transduction efficiency and virus tropism were assessed using flow cytometry. Around 6 % of the cells expressed GFP after transduction and both FLS (6.7 % of the 78.7 % 11-fibrau-positive cells) and MLS (5.3 % of the 38.0 % CD68-positive cells) were transduced (Additional file 2: Figure S2).
The CXCL10 promoter responsiveness in synovial micromasses
The effects of IL-10 protein on synovial micromasses
In this study we set out to study the therapeutic potential of disease-inducible gene therapy for OA using the CXCL10p-IL10 lentivirus in a synovial lining model resembling early-stage OA that includes both synovial fibroblasts and synovial macrophages. After digestion of a synovial tissue sample the cells were mixed with Matrigel to obtain a synovial micromass, in which both FLS and MLS migrated to the micromass edge to form a lining. After transduction with a lentiviral CXCL10-promoter reporter vector, the CXCL10 promoter could be significantly induced by pro-inflammatory stimulation. When the CXCL10 promoter drove the expression of the gene coding for anti-inflammatory IL-10, sufficient IL-10 could be produced to reduce the release of IL-1β and IL-6 after stimulation with TNF-α or LPS.
In vitro studies with human synovial cells are often performed in monolayer culture, in which the cells might behave and interact differently from the complex structural organization in the joint . To improve in vitro synovium studies, Kiener at al. developed a 3D synovial lining model . Primary FLS are mixed with Matrigel to form a micromass structure, in which the FLS migrate towards the outside to form a lining layer, a phenomenon not observed with dermal fibroblasts. The micromass lining shows many similarities to the synovial lining. It expresses the synovial fibroblast marker proteoglycan 4 (PRG4) and produces extracellular matrix . MLS were not included in these studies, but the FLS could support the survival of monocytes from peripheral blood.
Interestingly, macrophages in culture without the appropriate stimulation undergo apoptosis . Kiener et al. showed that primary monocytes from the blood are not viable in micromasses when cultured alone, but could survive for over 3 weeks when cultured together with FLS . We showed that the micromasses can also support the survival of synovial macrophages and that the macrophages resided in the lining. Because the micromasses do not show the fibrotic changes and macromolecular cartilage and bone detritus-rich synoviopathy observed in late-stage OA, the synovial micromass might more closely mimic early-stage OA compared to synovial explants from joint replacement remnants. This enables the possibility to test therapeutic strategies in an early disease stage where inhibition of inflammation might prevent disease progression.
During inflammation, synovial macrophages become activated and produce pro-inflammatory cytokines, matrix-degrading enzymes and promote synovial hyperplasia . The synovial micromass model based on primary tissue digestions can be a suitable model to study these processes. The inclusion of MLS in the micromasses is particularly important for testing IL-10-based therapies, since the primary receptor subunit for IL-10, IL-10 receptor subunit alpha (IL-10R1), is most strongly expressed on cells of hematopoietic origin [28, 29]. After transduction of the micromasses with lentiviral PGK-GFP, transgene expression was predominantly observed in the membrane, which is similar to observations with intra-articular injections of lentivirus in vivo , providing further support that micromasses are an adquate model for the synovial membrane.
IL-10 is a powerful anti-inflammatory cytokine and IL-10-based gene therapy has proven to be effective in multiple animal models of OA and cartilage damage, alone and in combination with IL-1 receptor antagonist (IL-1Ra) or interleukin-4 (IL-4) [31, 32]. Low innate production of IL-10 by blood cells upon lipopolysaccharide (LPS) stimulation ex vivo is associated with an increased risk of OA . In addition, it has been concluded from a systematic review that physical exercise has positive effects on pain and disability in knee OA . These effects might be mediated by IL-10, which was found to be upregulated in the synovial fluid after exercise . In addition to the inhibition of inflammation and matrix-degrading enzymes, IL-10 has chondroprotective and anabolic effects on cartilage by stimulating chondrocyte proliferation, stimulating the production of extracellular matrix components and reducing chondrocyte apoptosis [2, 36]. One of the mechanisms by which IL-10 can exert its anti-inflammatory effects, is by inducing the expression of SOCS3 . SOCS3 can inhibit Janus kinase signal transducer and activator of transcription (JAK-STAT) signaling induced by cytokine receptor activation . A second anti-inflammatory mechanism proposed for IL-10 is the inhibition of proteins that stabilize TNF-α messenger RNA (mRNA) . As a result, the TNF-α mRNA becomes prone to degradation mediated by the 3′UTR AU-rich elements (AREs). We have found both upregulation of SOCS3 and reduced levels of TNF-α mRNA after treatment with recombinant IL-10, indicating that IL-10 might inhibit the inflammatory response in synovial micromasses at multiple levels.
The levels of TNF-α, IL-1β and IL-6 are increased in OA patients and high levels are associated with increased radiographic progression . We have observed increased production of these cytokines by the micromasses under inflammatory conditions. TNF-α and IL-1β mRNA could be downregulated by IL-10 and the produced levels of IL-1β and IL-6 decreased after treatment with both PGK-IL10 and CXCL10p-IL10. Interestingly, the variation in basal IL-10 production between patients after transduction with CXCL10p-IL10 was bigger compared to the IL-10 production after stimulation with LPS or after transduction with PGK-IL10 (Fig. 4). The variation in basal IL-10 production from the CXCL10p-IL10-transduced micromasses might result from a variation in tissue composition or differences in inflammatory imprinting of synovial cells between patients rather than transduction efficiency, because less variation in IL-10 production after transduction with PGK-IL10 was observed.
We showed that 3D micromasses that are made from primary synovial cells of OA patients form a synovial lining consisting of fibroblast-like and macrophage-like synoviocytes and the micromasses might be a useful tool to study synovium in vitro. The micromass lining can be transduced by lentiviruses and provide disease-inducible expression of sufficient amounts of IL-10 to reduce the production of pro-inflammatory cytokines by the micromasses. Gene therapy with the CXCL10p-IL-10 vector might be a promising strategy for local treatment of early OA.
2D, two-dimensional; 3D, three-dimensional; ANOVA, analysis of variance; ARE, AU-rich element; CD68, cluster of differentiation 68; CXCL10, C-X-C motif chemokine 10; DAMP, damage-associated molecular pattern; DAPI, 4′,6-diamidino-2-phenylindole; ELISA, enzyme-linked immunosorbent assay; FCS, fetal calf serum; FLS, fibroblast-like synoviocytes; GFP, green fluorescent protein; HEMA, 2-hydroxyethyl methacrylate; HRP, horseradish peroxidase; H&E, hematoxylin and eosin; IL-1RA, interleukin-1 receptor antagonist; IL-1β, interleukin-1 beta; IL-4, interleukin-4; IL-6, interleukin-6; IL-10, interleukin-10; IL-10R1, IL-10 receptor subunit alpha; JAK-STAT, Janus kinase signal transducer and activator of transcription; LPS, lipopolysaccharide; MLS, macrophage-like synoviocyte; mRNA, messenger RNA; MCS, multiple cloning site; OA, osteoarthritis; PBS, phosphate-buffered saline; PGK, phosphoglycerate kinase; PRG4, proteoglycan 4, lubricin; qPCR, quantitative polymerase chain reaction; RA, rheumatoid arthritis; RLU, relative light units; RPL22, 60S ribosomal protein L22; RPMI, Roswell Park Memorial Institute; SOCS3, suppressor of cytokine signaling 3; TNF-α, tumour necrosis factor alpha
We would like to thank Jon San Liu for his CD68 staining of the synovial paraffin sections.
This study was financially supported by the Dutch Arthritis Foundation (11-1-409), the Netherlands Organization for Health Research and Development (ZonMw, 114021001) and the Innovative Medicines Initiative Joint Undertaking funded project BTCure (grant number: 115142-2).
Availability of data and materials
Our study did not yield datasets suitable to include in online repositories and no biological material was left to include in a biobank.
MGB performed the experiments, statistical analysis and drafted the manuscript. MdV assisted with the micromass culture and revised the manuscript. MBB and OA performed the experiments and helped to draft the manuscript. PvL, PK, WvdB, FvdH and MK assisted in the study design, interpretation of the data and helped draft the manuscript. FvdL assisted in the study design, interpretation of the data and revised the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
The patient samples used in this study were obtained after surgical intervention and therefore not part of the Medical Research Involving Human Subjects Act (WMO). Instead, we adhered to the Human Tissue and Medical Research: Code of Conduct for Responsible Use (2011) of the Stichting Federatie Medisch Wetenschappelijke Verenigingen (FEDERA) and the protocols were approved by the local CMO-light committee. All patients gave their informed consent.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377(9783):2115–26.View ArticlePubMedGoogle Scholar
- Wojdasiewicz P, Poniatowski LA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm. 2014;2014:561459.View ArticlePubMedPubMed CentralGoogle Scholar
- Bondeson J, Blom AB, Wainwright S, Hughes C, Caterson B, van den Berg WB. The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum. 2010;62(3):647–57.View ArticlePubMedGoogle Scholar
- Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther Adv Musculoskelet Dis. 2013;5(2):77–94.View ArticlePubMedPubMed CentralGoogle Scholar
- Chevalier X, Eymard F, Richette P. Biologic agents in osteoarthritis: hopes and disappointments. Nat Rev Rheumatol. 2013;9(7):400–10.View ArticlePubMedGoogle Scholar
- Wallis WJ, Simkin PA, Nelp WB. Protein traffic in human synovial effusions. Arthritis Rheum. 1987;30(1):57–63.View ArticlePubMedGoogle Scholar
- Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. 2012;32(1):23–63.View ArticlePubMedPubMed CentralGoogle Scholar
- Henningsson L, Eneljung T, Jirholt P, Tengvall S, Lidberg U, van den Berg WB, van de Loo FA, Gjertsson I. Disease-dependent local IL-10 production ameliorates collagen induced arthritis in mice. PLoS One. 2012;7(11):e49731.View ArticlePubMedPubMed CentralGoogle Scholar
- Vermeij EA, Broeren MG, Bennink MB, Arntz OJ, Gjertsson I, P LEMvL, van den Berg WB, Koenders MI, van de Loo FA. Disease-regulated local IL-10 gene therapy diminishes synovitis and cartilage proteoglycan depletion in experimental arthritis. Ann Rheum Dis. 2015;74(11):2084–91.View ArticlePubMedGoogle Scholar
- Garaulet G, Alfranca A, Torrente M, Escolano A, Lopez-Fontal R, Hortelano S, Redondo JM, Rodriguez A. IL10 released by a new inflammation-regulated lentiviral system efficiently attenuates zymosan-induced arthritis. Mol Ther. 2013;21(1):119–30.View ArticlePubMedGoogle Scholar
- Tilg H, Ulmer H, Kaser A, Weiss G. Role of IL-10 for induction of anemia during inflammation. J Immunol. 2002;169(4):2204–9.View ArticlePubMedGoogle Scholar
- Broeren MG, de Vries M, Bennink MB, Arntz OJ, Blom AB, Koenders MI, van Lent PL, van der Kraan PM, van den Berg WB, van de Loo FA. Disease-regulated gene therapy with antiinflammatory interleukin-10 under the control of the CXCL10 promoter for the treatment of rheumatoid arthritis. Hum Gene Ther. 2016;27(3):244–54.View ArticleGoogle Scholar
- Sohn DH, Sokolove J, Sharpe O, Erhart JC, Chandra PE, Lahey LJ, Lindstrom TM, Hwang I, Boyer KA, Andriacchi TP, et al. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4. Arthritis Res Ther. 2012;14(1):R7.View ArticlePubMedPubMed CentralGoogle Scholar
- Beekhuizen M, Gierman LM, van Spil WE, Van Osch GJ, Huizinga TW, Saris DB, Creemers LB, Zuurmond AM. An explorative study comparing levels of soluble mediators in control and osteoarthritic synovial fluid. Osteoarthritis Cartilage. 2013;21(7):918–22.View ArticlePubMedGoogle Scholar
- Lee EY, Lee ZH, Song YW. The interaction between CXCL10 and cytokines in chronic inflammatory arthritis. Autoimmun Rev. 2013;12(5):554–7.View ArticlePubMedGoogle Scholar
- Neidhart M, Jungel A, Ospelt C, Michel BA, Gay RE, Gay S. Deficient expression of interleukin-10 receptor alpha chain in rheumatoid arthritis synovium: limitation of animal models of inflammation. Arthritis Rheum. 2005;52(10):3315–8.View ArticlePubMedGoogle Scholar
- Cukierman E, Pankov R, Stevens DR, Yamada KM. Taking cell-matrix adhesions to the third dimension. Science (New York, NY). 2001;294(5547):1708–12.View ArticleGoogle Scholar
- Geurts J, Joosten LA, Takahashi N, Arntz OJ, Gluck A, Bennink MB, van den Berg WB, van de Loo FA. Computational design and application of endogenous promoters for transcriptionally targeted gene therapy for rheumatoid arthritis. Mol Ther. 2009;17(11):1877–87.View ArticlePubMedGoogle Scholar
- de Jonge HJ, Fehrmann RS, de Bont ES, Hofstra RM, Gerbens F, Kamps WA, de Vries EG, van der Zee AG, te Meerman GJ, ter Elst A. Evidence based selection of housekeeping genes. PLoS One. 2007;2(9):e898.View ArticlePubMedPubMed CentralGoogle Scholar
- Zimmermann T, Kunisch E, Pfeiffer R, Hirth A, Stahl HD, Sack U, Laube A, Liesaus E, Roth A, Palombo-Kinne E, et al. Isolation and characterization of rheumatoid arthritis synovial fibroblasts from primary culture--primary culture cells markedly differ from fourth-passage cells. Arthritis Res. 2001;3(1):72–6.View ArticlePubMedGoogle Scholar
- Bode JG, Nimmesgern A, Schmitz J, Schaper F, Schmitt M, Frisch W, Haussinger D, Heinrich PC, Graeve L. LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages. FEBS Lett. 1999;463(3):365–70.View ArticlePubMedGoogle Scholar
- Matsuno H, Yudoh K, Katayama R, Nakazawa F, Uzuki M, Sawai T, Yonezawa T, Saeki Y, Panayi GS, Pitzalis C, et al. The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford). 2002;41(3):329–37.View ArticleGoogle Scholar
- Perlman H, Pope RM. The synovial lining micromass system: toward rheumatoid arthritis in a dish? Arthritis Rheum. 2010;62(3):643–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Kiener HP, Lee DM, Agarwal SK, Brenner MB. Cadherin-11 induces rheumatoid arthritis fibroblast-like synoviocytes to form lining layers in vitro. Am J Pathol. 2006;168(5):1486–99.View ArticlePubMedPubMed CentralGoogle Scholar
- Kiener HP, Watts GF, Cui Y, Wright J, Thornhill TS, Skold M, Behar SM, Niederreiter B, Lu J, Cernadas M, et al. Synovial fibroblasts self-direct multicellular lining architecture and synthetic function in three-dimensional organ culture. Arthritis Rheum. 2010;62(3):742–52.View ArticlePubMedGoogle Scholar
- Wang ZQ, Bapat AS, Rayanade RJ, Dagtas AS, Hoffmann MK. Interleukin-10 induces macrophage apoptosis and expression of CD16 (FcgammaRIII) whose engagement blocks the cell death programme and facilitates differentiation. Immunology. 2001;102(3):331–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Bondeson J. Activated synovial macrophages as targets for osteoarthritis drug therapy. Curr Drug Targets. 2010;11(5):576–85.View ArticlePubMedGoogle Scholar
- Nagalakshmi ML, Murphy E, McClanahan T, de Waal MR. Expression patterns of IL-10 ligand and receptor gene families provide leads for biological characterization. Int Immunopharmacol. 2004;4(5):577–92.View ArticlePubMedGoogle Scholar
- Mrosewski I, Jork N, Gorte K, Conrad C, Wiegand E, Kohl B, Ertel W, John T, Oberholzer A, Kaps C, et al. Regulation of osteoarthritis-associated key mediators by TNFalpha and IL-10: effects of IL-10 overexpression in human synovial fibroblasts and a synovial cell line. Cell Tissue Res. 2014;357(1):207–23.View ArticlePubMedGoogle Scholar
- Gouze E, Pawliuk R, Pilapil C, Gouze JN, Fleet C, Palmer GD, Evans CH, Leboulch P, Ghivizzani SC. In vivo gene delivery to synovium by lentiviral vectors. Mol Ther. 2002;5(4):397–404.View ArticlePubMedGoogle Scholar
- Zhang X, Mao Z, Yu C. Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10. J Orthop Res. 2004;22(4):742–50.View ArticlePubMedGoogle Scholar
- van Meegeren ME, Roosendaal G, Jansen NW, Wenting MJ, van Wesel AC, van Roon JA, Lafeber FP. IL-4 alone and in combination with IL-10 protects against blood-induced cartilage damage. Osteoarthritis Cartilage. 2012;20(7):764–72.View ArticlePubMedGoogle Scholar
- Riyazi N, Slagboom E, de Craen AJ, Meulenbelt I, Houwing-Duistermaat JJ, Kroon HM, van Schaardenburg D, Rosendaal FR, Breedveld FC, Huizinga TW, et al. Association of the risk of osteoarthritis with high innate production of interleukin-1beta and low innate production of interleukin-10 ex vivo, upon lipopolysaccharide stimulation. Arthritis Rheum. 2005;52(5):1443–50.View ArticlePubMedGoogle Scholar
- Roddy E, Zhang W, Doherty M. Aerobic walking or strengthening exercise for osteoarthritis of the knee? A systematic review. Ann Rheum Dis. 2005;64(4):544–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Helmark IC, Mikkelsen UR, Borglum J, Rothe A, Petersen MC, Andersen O, Langberg H, Kjaer M. Exercise increases interleukin-10 levels both intraarticularly and peri-synovially in patients with knee osteoarthritis: a randomized controlled trial. Arthritis Res Ther. 2010;12(4):R126.View ArticlePubMedPubMed CentralGoogle Scholar
- Jung YK, Kim GW, Park HR, Lee EJ, Choi JY, Beier F, Han SW. Role of interleukin-10 in endochondral bone formation in mice: anabolic effect via the bone morphogenetic protein/Smad pathway. Arthritis Rheum. 2013;65(12):3153–64.View ArticlePubMedGoogle Scholar
- Shen X, Hong F, Nguyen VA, Gao B. IL-10 attenuates IFN-alpha-activated STAT1 in the liver: involvement of SOCS2 and SOCS3. FEBS Lett. 2000;480(2-3):132–6.View ArticlePubMedGoogle Scholar
- Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003;3(11):900–11.View ArticlePubMedGoogle Scholar
- Rajasingh J, Bord E, Luedemann C, Asai J, Hamada H, Thorne T, Qin G, Goukassian D, Zhu Y, Losordo DW, et al. IL-10-induced TNF-alpha mRNA destabilization is mediated via IL-10 suppression of p38 MAP kinase activation and inhibition of HuR expression. FASEB J. 2006;20(12):2112–4.View ArticlePubMedGoogle Scholar
- Wenham CY, Conaghan PG. The role of synovitis in osteoarthritis. Ther Adv Musculoskelet Dis. 2010;2(6):349–59.View ArticlePubMedPubMed CentralGoogle Scholar